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Of special interest is the evolution of the SARS-CoV-2 surface
protein, spike (S), which is responsible for viral entry via its inter-
action with the human angiotensin-converting enzyme 2 (hACE2)
receptor on host cells. The S protein is the target of neutralizing
antibodies generated by infection (Jiang et al., 2020) or vaccina-
tion (Folegatti et al., 2020; Jackson et al., 2020; Keech et al.,
2020) as well as monoclonal antibody (mAb) drugs currently in
clinical trials and/or approved for Emergency Use Authorization
(EUA) by the US Food and Drug Administration (FDA) (Chen
et al., 2021; Hansen et al., 2020; Jones et al., 2020; Pinto
et al., 2020).
A SARS-CoV-2 S amino acid change, D614G, is nowdominant
in most places around the globe (Korber et al., 2020). Studies
in vitro indicate that this mutation confers greater infectivity while
molecular epidemiology correlates it with an increase in trans-
missibility with no evidence to date for increased virulence
(Hou et al., 2020; Hu et al., 2020; Korber et al., 2020; Volz et
al., 2021; Zhang et al., 2020). Amino acid 614 is located outside
the receptor binding domain (RBD) of S, the domain targeted by
90% of neutralizing antibody activity in serum of SARS-CoV-2
survivors (Piccoli et al., 2020). Initial studies suggest that
D614G viruses exhibit increased sensitivity to neutralizing anti-
bodies, likely due to the effect of the mutation on the molecular
dynamics of the S protein (Hou et al., 2020; Weissman et al.,
2021; Yurkovetskiy et al., 2020). Therefore, this now dominant
variant is unlikely to jeopardize natural or vaccine-derived anti-
body-mediated immunity generated in response to D614 S
protein.
The low numbers of novel mutations reaching high frequency
in sequenced SARS-CoV-2 genomes relates to the moderate
intrinsic error rate of SARS-CoV-2 RNA replication (Li et al.,
2020c; Robson et al., 2020). Nevertheless, the increasing num-
ber of infected individuals and the large reservoir of hosts sus-
ceptible to infection increase the likelihood that novel variants
that impact vaccine and therapeutic development will emerge1172 Cell 184, 1171–1187, March 4, 2021and spread by chance. Moreover, the full impact of immune se-
lection, which can drive variant selection, has not yet influenced
the pandemic, because herd immunity has not been attained. As
population immunity increases and vaccines are deployed at
scale, this will very likely change. The potential for circulating
viral variants to derail promising vaccine or antibody-based pro-
phylactics or treatments, even in the absence of selective pres-
sure from the drug or vaccine, is demonstrated by the failure of a
phase III clinical trial of a mAb targeting the respiratory syncytial
virus (Simões et al., 2020) and the need for new influenza vac-
cines on a yearly basis. It is therefore critical to understand
whether and how SARS-CoV-2 may evolve to evade antibody-
dependent immunity.
Here, we examine the immunodominant SARS-CoV-2 recep-
tor binding motif (RBM), the primary target of the neutralizing
Ab response within the RBD (Piccoli et al., 2020), and find it to
be a highly variable region of the S protein in circulating viruses.
To understand the implications of this structural plasticity, which
could allow the RBD to accommodate amino acids changes
that could contribute to immune evasion, we defined the clinical
and epidemiological impact, molecular features, and immune
response to the RBMmutation N439K. This amino acid replace-
ment has arisen independently multiple times, and in two cases
formed lineages of more than 500 sequences. As of January 6,
2021, it was observed in 34 countries and was the second
most commonly observed RBD mutation worldwide, and the
sixthmost common Smutation.We find that the N439Kmutation
results in enhancedRBD affinity for hACE2, it is associatedwith a
similar clinical spectrum of disease and slightly higher viral loads
in vivo compared to viruses with the wild-type (WT) N439 resi-
due, and it results in immune escape from polyclonal sera
from a proportion of recovered individuals and some neutralizing
mAbs.
N439K provides a sentinel example of immune escape, indi-
cating that RBM variants must be evaluated when considering
vaccines and the therapeutic or prophylactic use of mAbs.
Figure 1. The RBM exhibits significant natu-
ral diversity in circulating SARS-CoV-2 vi-
ruses
SARS-CoV-2 variants (retrieved from CoV-
GLUE) are based on 209,239 high-quality se-
quences downloaded from GISAID on November
30, 2020.
(A) Structure of the SARS-CoV-2 RBD-hACE2
complex (PDB: 6M0J) highlighting the RBM
(blue) and residue N439 (yellow).
(B) Thirty-four residues (the size of the RBM)
were randomly sampled without replacement
50,000 times from the mature S protein
(excluding the RBM). Median entropies were
computed for each draw. The resulting 50,000
median entropies were used to build the entropy
distribution of residues other than the RBM. The
top 10% medians are highlighted in red. The
median entropy of RBM residues was compared
with the non-RBM entropy distribution to deter-
mine the variability of the RBM relative to non-
RBM residues. To allow for a fair comparison,
sampling was performed without enforcing res-
idue contiguity, as the RBM is not contiguous in
sequence space. Therefore, in any given sam-
ple, residues are unlikely to share any functional
relationship.
(C) Per-residue entropies of the mature S protein
were smoothed by plotting medians of a 25-aa
center-aligned sliding window. Smoothing al-
lows visualizing local peaks of variability. The
RBM residues and the NTD, RBD, and S2 do-
mains are highlighted. Due to the non-contiguous nature of the RBM in sequence space, the sliding window median at RBM residues is diluted by
neighboring non-RBM residues.
(D) Boxplot of per-residue entropies in four S domains (or full mature S protein). The lower and upper hinges correspond to the first and third quartiles. The
lower/upper whiskers extend from the hinge to the smallest/largest value no further than 1.5 times the inter-quartile range. Outliers beyond the end of the
whiskers are not plotted but are retained for statistical testing. Pairwise comparisons by Mann-Whitney U tests. p value thresholds are 0.05 (*), 0.01 (**) and
0.001 (***); ns, not significant.
See also Figures S1 and S2.
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systematic monitoring of immune escape variants and may
require new vaccine preparations that address the variants
circulating globally.
RESULTS
The RBM is a variable region of the SARS-CoV-2 S
protein
Competing pressures influence the evolution of the S RBM. First,
the RBM mediates viral entry (Shang et al., 2020; Walls et al.,
2020;Wrapp et al., 2020b) and therefore mustmaintain sufficient
affinity to engage the entry receptor hACE2. Second, it is a major
target of neutralizing antibodies (Piccoli et al., 2020; Robbiani
et al., 2020; Rogers et al., 2020; Wec et al., 2020) and so would
be a primary location for the emergence of immune escape mu-
tations. We set out to understand these competing pressures
by evaluating the landscape of RBM sequence divergence
observed in circulating SARS-CoV-2 variants and in other vi-
ruses of the Sarbecovirus lineage.
We used re-refined published X-ray structures of SARS-CoV
and SARS-CoV-2 RBD:hACE2 complexes (Lan et al., 2020; Li
et al., 2005) to define the RBM residues using a 6 Å distance cut-off (Figures 1A–1D and S1A, 2). We evaluated SARS-CoV-2
genomic sequences deposited in GISAID as of November
30th, 2020 and observed a high number of variants occurring
in the RBM. To understand how the variability of the RBM com-
pares to the variability of the entire RBD and the whole S protein,
we evaluated well-defined S protein domains: within S1, the
N-terminal domain (NTD) and the RBD (further split into RBM
and non-RBM), and the S2 domain. Analysis of entropy, which
estimates sequence variability at a given position in a protein
alignment, identified the RBM as a highly variable region of the
RBD and of the entire S protein (Figures 1B–1D), with a median
entropywithin the top 10%of equivalently sized sets of randomly
sampled residues (Figure 1B). This result is confirmed by an anal-
ysis of sequence variability that is not weighted by total counts
of each variant, thereby capturing the diversity of circulating
variants with mitigated bias toward oversampled variants
(Figure S1A).
To understand constraints on RBM variability, we evaluated
the published deep mutational scanning (DMS) dataset of the
RBD (Starr et al., 2020b) and compared it to sequences of circu-
lating viruses. The DMS data define the effect of each possible
single amino acid change on both expression of the RBD and
its capacity to bind hACE2. For each position in the RBM, weCell 184, 1171–1187, March 4, 2021 1173
Figure 2. RBM functional constraints compared to RBM natural
diversity
Each residue in the RBM is annotated by several metrics, depicted as a
heatmap. DMS scores: outlined in black boxes (center) are summaries of
hACE2 binding and RBD expression deep mutational scanning (DMS) exper-
imental results (Starr et al., 2020b). DMS score is the binding or expression fold
change of a variant over WT on a log10 scale (red indicating improvement and
blue indicating loss as compared to WT). In the ‘‘mutagenesis’’ columns, DMS
results are given for each residue as either the minimum (most disruptive
variant) or the average score across all possible variants of a residue, except
for the reference residue and the stop codon. In the ‘‘observed variants’’
columns, minimum and average scores are computed only across variants
that have been observed in GISAID (same set of sequences as used for Fig-
ure 1). When no natural variants have been observed, cells are gray. Data were
sorted on the leftmost DMS column. Frequency: each RBM position is anno-
tated with the frequency of non-reference amino acids in deposited sequences
(darker red indicating higher frequency; at least 1 supporting sequence per
25,000 deposited sequences is required to call a variant). The number of
countries in which variants have been observed is also annotated (darker
ll
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Articlecompared the DMS results for all amino acid replacements at
that position versus only changes that have been observed in
circulating SARS-CoV-2 variants (Figure 2). A subset of residues
shows the largest loss of hACE2 binding onmutation (top1/3 of
RBM residues in Figure 2) and, as would be expected, few nat-
ural occurrences of mutations at these residues have been
observed to be circulating. However, for the majority of the
RBM (bottom 2/3 of RBM residues in Figure 2), variation in
circulating virus sequences confirms the tolerance to mutation
predicted by the DMS data.
To further assess the ability of the RBM to accommodate mu-
tations without disrupting hACE2 binding, we examined the
structural dynamics and energetics of the RBM:hACE2 binding
interface. We performed an approximate, residue-level decom-
position of binding free energy based on the RBD:hACE2
complex X-ray structure (green in Figure 2) as well as molecular
dynamics simulations of the complex, resulting in 118 ms of
aggregate simulation data (Figure S1B). Consistent with expec-
tation, the two residues with the highest variant frequency (S477
and N439) contribute weakly to the binding energy (Figure 2).
Surprisingly, the two RBM residues with the strongest interac-
tions with hACE2 based on the X-ray structure (K417 and
E484, dark green in Figure 2) were not highly conserved (variant
% in red, Figure 2), with 10-fold more variants for E484. This
could be explained by results from the molecular dynamics
simulation: K417 formed close interactions with hACE2 70% of
the simulation time, while E484 only 3% of the time (Figure S1B).
The low percent for E484 is also consistent with the non-conser-
vative amino acid replacements observed for circulating variants
(e.g., the most common E484 substitution is currently E484K),
with a positively charged lysine substituting for the negatively
charged glutamate. Overall, these results demonstrate that the
RBM has a high degree of structural plasticity whereby it is
able to accommodate amino acid changes without disrupting
hACE2 binding.
Evolutionary analysis of the Sarbecovirus subgenus provides
further support for RBM plasticity (Boni et al., 2020; Li et al.,
2020b; Rambaut et al., 2020). The SARS-CoV RBM is highly
divergent from the SARS-CoV-2 RBM (Figures S2A and S2B)
while maintaining hACE2 binding affinity. Additionally, there are
many sequence changes in the RBM across a panel of related
coronaviruses from animal isolates (Figures S2A and S2B; Table
S1). To determine the ability of members of the Sarbecovirus
lineage to bind hACE2, we produced nine recombinant RBD pro-
teins corresponding to seven animal isolates, SARS-CoV-2, and
SARS-CoV, and evaluated their binding to recombinant hACE2
(Figure S2C). We found that three of the RBDs from animal iso-
lates showed strong affinity for hACE2: GD Pangolin, which
has a highly similar RBM to SARS-CoV-2, GX Pangolin, which
has a more divergent RBM, and Bat CoV WIV1 which is highlypurple indicating more countries). Binding energy: a re-refined SARS-CoV-2
RBD:hACE2 complex X-ray structure (PDB: 6M0J) was used to determine the
approximate, decomposed binding free energy associated with each RBM
residue. Results for each RBM residue are expressed as a percentage of the
total binding interface interaction energy (darker green indicating stronger
contribution to the binding energy).
See also Figures S1 and S2.
Figure 3. The N439K RBM mutation has
arisen independently multiple times, twice
forming significant lineages
(A) Phylogenetic tree (de-duplicated and down-
sampled) showing the relationship among repre-
sentative global SARS-CoV-2 variants, with N439K
variants highlighted in color. Two significant
N439K lineages, one in Scotland (>500 sequences,
blue circles) and one in 32 countries (>6,000 se-
quences, yellow circles) were detected as of
January 6, 2021. The N439K mutation has also
emerged independently on at least seven occa-
sions (red circles show four of these) bringing the
total country count to 34. Vertical bars indicate
global lineage, the presence of N439K (same
colors as tree), D614G (orange) or D614N (dark
gray). The scale bar corresponds to a single
nucleotide polymorphism (SNP).
(B) Frequency of N439K variants relative to sam-
pling time and their geographical area of occur-
rence (see key): Africa (Morocco, Nigeria), Amer-
icas (Brazil, USA), Asia (Japan, Singapore, South
Korea), the European countries Denmark, England,
Republic of Ireland and Scotland and other Euro-
pean countries (Belgium, Bosnia-Herzegovina,
Croatia, Czech Republic, Faroe Islands, Finland,
France, Germany, Hungary, Italy, Luxembourg,
Netherlands, Northern Ireland, Norway, Poland,
Romania, Slovakia, Sweden, Switzerland, Wales),
and Oceania (Australia, New Zealand). The prom-
inent light gray bars correspond to other European countries. See Table S2 for total numbers for each country.
(C) Frequency of the two N439K lineages (same colors as A) over time relative to all sequences for that country (gray) and their normalized contributions (lower
panels) in Scotland, England, Republic of Ireland, and Denmark.
See also Figure S3.
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RBM is structurally plastic, retaining binding with hACE2 as a re-
ceptor despite changes to sequence. Given this plasticity, we
next considered whether an RBM variant can lead to immune
evasion while retaining virulence.
Phylogenetic analysis of the prevalent SARS-CoV-2
RBM mutation N439K
N439K is a prevalent RBM mutation (the second most common
mutation in the RBD through the end of 2020) which was first
sampled in March 2020 in Scotland from lineage B.1 (Rambaut
et al., 2020) on the background of D614G. Using phylogenetic
analysis, we determined that the earliest reported N439K se-
quences represented a single SARS-CoV-2 lineage (Figure 3A)
that increased in frequency to 542 sequences in Scotland by
June 20, 2020 (10% of the available Scottish viral genome se-
quences for this time period). Subsequently, numbers of N439K
and all other variants decreased in Scotland concurrent with
control of the pandemic after initiation of stringent public health
measures, with this specific N439K lineage (designated here as
lineage i) not being detected since June 2020 (Figures 3B and
3C). However, the N439K mutation appears in >6,000 additional
sequences in the GISAID database as of January 6, 2021. Our
analysis demonstrates that the majority of these sequences
represent a second, independent lineage (designated lineage ii)
which was first sampled in Romania on May 13, 2020, then Nor-
way on June 23, 2020, and is now detected to be circulating in 32countries (Figures 3A–3C). N439K lineages i and ii have recently
received the lineage designations B.1.141 and B.1.258, respec-
tively (Rambaut et al., 2020). We also observe at least seven in-
stances of the N439Kmutation that have arisen independently of
these two large lineages, including again in the United States in
at least four linked infections, and in Brazil and Nigeria where no
lineage ii/B.1.258 has been observed, resulting in a total of 34
countries where N439K has been detected to date (Figures 3A
and 3B).
Sequence counts are heavily influenced by sampling fre-
quency, which varies widely between countries, and N439K as
a percentage of total sequences appears low: as of January 6,
2021, there have been 6,868 N439K observations in GISAID,
2% out of 290,000 SARS-CoV-2 genome sequences for the
34 countries where this mutation has been detected (Table
S2). Nevertheless, when comparing the percentage of N439K
sequences over time in countries with sufficient data, the propor-
tion can be significant: 10% in Scotland from March to June
2020 and 10% in Denmark from August to December 2020,
both countries with high sequencing rates, and 13% in Ireland
from July to December 2020, where regional coverage is reason-
able, but the sequencing rate is lower (Figure 3C). Importantly, on
the scale of a pandemic, small proportions correspond to large
numbers of infections. If the proportion of N439K sequences in
each country predicts what proportion of its confirmed infections
are associated with N439K variants, then N439K variants corre-




D Figure 4. N439K creates a new RBD:hACE2
salt bridgeandenhancesRBD:hACE2affinity
(A–C) X-ray structures of the SARS-CoV (A), SARS-
CoV-2 WT (B), and SARS-CoV-2 N439K (C) RBD in
complex with hACE2 (based on 2AJF, 6M0J, and
current work, respectively). Select interface resi-
dues are shown as sticks. hACE2 is shown in or-
ange and RBD in gray. The inset in (C) shows the
2Fo-Fc electron density contoured at 1s for the
K439-E329 salt bridge.
(D) Binding affinity of RBD and Spike variants for
hACE2 measured by surface plasmon resonance.
Monomeric hACE2 is injected successively at 11,
33, 100, and 300 nM onto surface-captured spike
extracellular domain (ECD) or RBD; alternately,
RBD is injected successively at 3.1, 12.5, and 50nM
onto surface-captured hACE2. All spike ECD
contain the D614G mutation. Bar graph: affinity
measurements (averages of 3–4 replicates) ex-
pressed as a fold change relative to WT binding
within each experiment format, where >1 indicates
improved binding (smaller KD) relative toWT.WTKD
values measured as: 95 ± 1.6 nM (Spike surface),
63 ± 1.0 nM (RBD surface), 19 ± 3.3 nM (hACE2
surface); errors are SEM.
See also Table S3.
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33% of true infections, as has been estimated for the United
States (Wu et al., 2020b), then a very rough approximation of
the actual cumulative number of N439K-associated infections
would be in the range of 2–15 million.
Overall, the spread of N439K to at least 34 countries is con-
cerning, as is its repeated independent emergence. At the nucle-
otide level, all N439K variants to date have arisen from the same
mutation: a C-to-A transversion in the third codon position. Inter-
estingly, 4,209 of sequences in lineage ii/B.1.258 also carry the S
69-70 deletion that has occurred independently multiple times in
the pandemic and most notably with the Y453F amino acid
replacement associated with mink infections (Oude Munnink
et al., 2021). In both cases the 69-70 deletionmutation has arisen
subsequent to the RBM mutation and then been retained in all
subsequent variants. This deletion has also been recently re-
ported to provide an escape for NTD-specific neutralizing anti-
bodies (McCarthy et al., 2021). Very recently, this deletion has
also been observed to co-occur with another RBM mutation,
N501Y (Volz et al., 2021).
Because there is concern that mutations with high prevalence
may have increased virus transmissibility, we next evaluated
whether any difference could be detected in the rate of spread of
the N439K lineages as compared to other lineages. Because Scot-
landhasahighsampling frequency for itspopulationsize (TableS2),
it is possible to calculate a growth rate for N439K lineage i based on
a comparisonwith other Scottish lineages (see STARmethods and
http://sars2.cvr.gla.ac.uk/RiseFallScotCOVID/). We find that while
the N439K/D614G lineage is one of the largest to emerge in Scot-1176 Cell 184, 1171–1187, March 4, 2021land, its growth rate is similar to themedian
N439/D614 or N439/D614G WT growth
rates, with no evidence for a faster growthconferred by the N439K mutation (Figure S3A).
N439KRBD forms a new interactionwith hACE2 and has
enhanced hACE2 affinity
In addition to its frequency and repeated emergence, the N439K
mutation stood out from other circulating RBMmutations as hav-
ing a plausible mechanism for maintenance of viral fitness. The
equivalent position to N439K in the SARS-CoV RBM is also a
positively charged amino acid (R426), which forms a salt bridge
with hACE2 (Li et al., 2005) (Figure 4A). We therefore hypothe-
sized that the N439K SARS-CoV-2 variant may form a similar
salt bridge at the RBD-hACE2 interface (RBD N439K:hACE2
E329) (Figure 4B). We determined the X-ray structure of the
N439K RBD in complex with hACE2 at 2.8 Å resolution and
observed that this new interaction does indeed form (Figure 4C;
Table S3). Because salt bridges can be strong non-covalent
bonds, and therefore the N439K mutation plausibly adds a
strong interaction at the binding interface, we hypothesized
that the N439K variant has enhanced binding for hACE2.
To test this hypothesis, we used surface plasmon resonance
(SPR) to evaluate binding of recombinant N439K S or RBD pro-
tein to recombinant hACE2. We also evaluated the N439R and
K417V variants, each of which are found in SARS-CoV at these
positions, and the latter of which would remove a salt bridge at
the RBD:hACE2 interface. Across multiple assay formats, we
found that the N439K and N439R variants exhibited an 2-fold
enhanced binding affinity for hACE2 as compared to the original
N439 variant (termed herein WT) (Figure 4D). The magnitude of
this enhancement was paralleled by an 2-fold loss of binding
Figure 5. Clinical outcomes and virological
evaluation of N439K lineage i indicate main-
tenance of fitness relative to WT virus
(A) Epidemiological growth of the N439/D614,
N439/D614G, or N439K/D614G virus in the Na-
tional Health Service (NHS) Greater Glasgow and
Clyde (GGC) Health Board area relative to sam-
pling time in epidemiological (epi) weeks (top) and
their relative contributions (bottom) for 1,918 pa-
tients whose diagnostic samples were sequenced.
(B) Top: real-time PCR data for N439/D614, N439/
D614G, and N439K/D614G groups, same patient
population as in (A). The N439K genotype was
associatedwithmarginally lower Ct values than the
N439 genotype (posteriormeanCt value difference
between N439K/D614G and N439/D614G: 0.65,
95% CI: 1.22, 0.07). Bottom: correlation be-
tween Ct and quantitative viral load.
(C) Severity of disease within NHS GGC for a
subset of 1,591 patients. Ordinal scale scored by
requirement for supplementary oxygen: (1) no
respiratory support, (2) supplemental oxygen, (3)
invasive or non-invasive ventilation or oxygen
delivered by high-flow nasal cannula, and (4)
death. Ordinal regression analysis indicated that
the N439K viral genotype was associated with
similar clinical outcomes compared to the N439
genotype (posterior mean of N439K/D614G ge-
notype effect: 0.06, 95% CI: 1.21, 1.33).
(D) Growth curves for GLA1 (N439/D614G) or
GLA2 (N439K/D614G) virus isolates in Vero
E6 cells with ACE2 and TMPRSS2 over-
expression (+TMPRSS2 +ACE2), ACE2 over-
expression (+ACE2), or no overexpression. Error
bars are SD from three replicates.
(E) Competition of GLA1 and GLA2 virus isolates
for growth in Vero E6 cells with ACE2 and
TMPRSS2 overexpression (+TMPRSS2 +ACE2),
ACE2 overexpression (+ACE2), or no over-
expression, after inoculation at a matched MOI.
Quantification of each virus was performed by
tracking the frequency of N439K within the spike
gene using metagenomic NGS. Error bars are SD
from three replicates.
See also Figure S3 and Tables S4–S6.
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with the DMS results (Starr et al., 2020b), which show a 2-fold
loss of binding for K417V and no change for N439K/R, as the
two assays are inherently different and the DMS data are much
higher-throughput but lower sensitivity. We also tested the effect
of the N439K/R and K417V mutations in combination. These
double mutants swap one salt bridge at the hACE2 binding inter-
face at RBD position 417 for one at position 439; we found they
had an hACE2 affinity similar to the WT (Figure 4D).
Overall, these data indicate that acquisition of the N439K mu-
tation enhances hACE2 binding, which could have implications
in vivo in the context of infection and transmission. At aminimum,
we found no evidence for any decreased success of N439K line-
age i relative to other lineages present in Scotland at the same
time (Figure S3A). The enhanced affinity could compensate for
other mutations that would otherwise decrease binding (e.g.,
K417V), further highlighting the plasticity of the RBM and the
need for surveillance.N439K SARS-CoV-2 maintains fitness and virulence
The enhanced hACE2 affinity conferred by the N439K mutation,
its geographical emergence as independent lineages, as well as
its prevalence among circulating viral isolates is consistent with
no effect on viral fitness. We set out to directly examine N439K
impact on viral fitness by evaluating clinical data and outcomes
associated with virus carrying the N439K mutation versus WT
N439, as well as by direct in vitro viral growth and competition.
Clinical data including age, gender, date of diagnosis, hospitali-
zation status, and mortality were collected prospectively, and
sequencing was carried out in real time, as part of the Scottish
strategy for COVID-19 surveillance.
We used qPCR to evaluate viral load (as measured by cycle
threshold [Ct]) in 1,918 Scottish patients whose positive samples
had been sequenced (Figures 5A and 5B). Variants were either
N439K/D614G (n = 406), N439/D614G (n = 978), or ancestral
(N439/D614) (n = 534). Our analysis found strong evidence that
theN439K/D614Ggenotypewasassociatedwithmarginally lowerCell 184, 1171–1187, March 4, 2021 1177
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founders: age,sex, viral co-ancestry,andepidemicstage (meanCt
value difference between N439K/D614G and N439/D614G:
0.65, 95%confidence interval [CI]:1.22,0.07) (Figure 5B; Ta-
ble S4). Assuming the PCRwas 95% efficient, then a mean Ct dif-
ference of 0.65 would represent an RNA copy number increase of
1.54-fold in N439K/D614G relative to N439/D614G. Because Ct
measurements were from multiple locations in Scotland, a sub-
analysis of viral load using RNA standards was carried out with
available samples. This analysis showed a near-complete correla-
tionwithCt values (Figure 5B). D614Ghas previously been associ-
ated with higher viral loads/lower Ct values (Korber et al., 2020;
Lorenzo-Redondo et al., 2020; Mueller et al., 2020; Volz et al.,
2021); althoughour data suggest a similar trend in a naive analysis,
when controlling for confounders (given above), we could not
detect this effect (Table S4).
Clinical outcomes were also obtained for a subset of these pa-
tients (n = 1,591), who were scored for severity of disease based
on oxygen requirement: (1) no respiratory support, (2) supple-
mental oxygen, (3) invasive or non-invasive ventilation or high
flow nasal cannula, or (4) death (Figures 5C and S3B). The
requirement for oxygen therapy or ventilation was collected
retrospectively. Variant counts for the clinical outcome analysis
were double mutant (N439K/D614G, n = 399), D614G mutants
(with N439 WT, n = 735), or ancestral genotype (N439/D614,
n = 457). Our ordinal regression indicated that the N439K/
D614G viral genotype was associated with similar clinical out-
comes compared to D614G or ancestral genotypes (posterior
mean of N439K/D614G genotype effect: 0.06, 95% CI: 1.21,
1.33) (Table S5). All other results from the severity analysis
were qualitatively similar to a previous analysis of the D614Gmu-
tation (Volz et al., 2021). These clinical outcome data indicate
that the N439K virus is neither linked to an attenuated phenotype
nor linked to increased severity.
We next experimentally tested growth of two representative
SARS-CoV-2 isolates, GLA1 (N439) and GLA2 (N439K), both
with the D614G background (Table S6). Culture was carried
out for 72 h in Vero E6 cells with either hACE2 and TMPRSS2
overexpression, hACE2 overexpression, or no overexpression.
There was no significant difference between the growth of these
isolates after inoculation at multiplicities of infection (MOIs) of
0.005 and 0.01. The N439K variant replicated slightly faster
initially after inoculation (Figure 5D). These experimental data
indicate that the N439K mutation does not exhibit positive or
negative effects on viral growth. To further assess fitness for
replication in cultured cells, we carried out a cross-competition
assay using inoculation of cells at a matched MOI followed by
quantitation of N439 and N439K by metagenomic sequencing
over time (Figure 5E). N439K demonstrated similar fitness as
the WT N439 variant, with a slight fitness advantage for N439K
in cells expressing TMPRSS2. Collectively, these results indicate
that the N439K mutation results in viral fitness that is similar or
possibly slightly improved relative to the WT N439 virus. These
results may relate to the improved hACE2 affinity measured for
the N439K RBD in the SPR binding assays, or could relate to
additional mechanisms, such as changes to S density on the viral
particle surface or changes to the conformational dynamics of
the S protein.1178 Cell 184, 1171–1187, March 4, 2021The N439K mutation promotes evasion of antibody-
mediated immunity
Having established that the N439K mutation has no detectable
effect on virus replication, we sought to test whether it promotes
evasion of antibody-mediated immunity by evaluating recogni-
tion of N439K RBD by mAbs and by polyclonal immune serum
from 442 recovered individuals, including six donors who were
infected by the SARS-CoV-2 N439K variant. 6.8% of the tested
sera showed a >2-fold reduction in binding to N439K RBD as
compared to WT (Figures 6A, 6B, and S4; Data S1). In some in-
dividuals, the >2-fold reduction diminished the RBD ED50
response below 30 (Figure 6A; Data S1), a threshold previously
determined to be a cutoff for specific binding (Piccoli et al.,
2020). Thus, the response to the RBD can be significantly influ-
enced by the N439Kmutation in a number of individuals infected
by WT SARS-CoV-2. The majority of serum samples for which
there was a loss of binding were those that had overall lower
Ab titers against WT RBD. The sera from the six individuals
known to have recovered from infection with SARS-CoV-2
N439K virus all showed <2-fold change in binding levels to WT
RBD as compared to N439K RBD (Figures 6A, 6B, and S4).
This may reflect a true variant-specific response or that differen-
tial binding could not be measured due to the limited number of
samples analyzed.
To understand our results at the level of individual antibodies,
we evaluated a panel of 140 mAbs isolated from individuals
recovered from SARS-CoV-2 infection early in the pandemic
(likely N439 WT virus), which are a representative sample of
the RBD-targeting mAbs generated after infection (Piccoli
et al., 2020; Tortorici et al., 2020). We also evaluated mAbs
REGN10933, REGN10987, LY-CoV555, and S309 (the parent
of VIR-7831) which are either clinical stage or approved for
EUA (Baum et al., 2020; Chen et al., 2021; Hansen et al., 2020;
Pinto et al., 2020). 16.7% of these mAbs demonstrated a >2-
fold reduction of RBD binding in response to the N439Kmutation
(Figures 6C, 6D, and S5; Data S1). For comparison, we also eval-
uated the K417V and N439K/K417V mutations. A similar per-
centage, 9.7% for K417V and 14.6% for N439K/K417V, lost
>2-fold binding to these variants (Figures 6C, 6D, and S5; Data
S1). Of note, some mAbs demonstrated a larger loss of binding
to the double mutant as compared to either single mutant (Fig-
ures 6C, 6D; and S5; Data S1). The reduced binding of mAbs
to these RBD mutants was also confirmed by bio-layer interfer-
ometry analysis (Figures 6E and S6). The mAb panel was evalu-
ated by RBD-binding competition experiments with hACE2 as
well as with three structurally characterized antibodies defining
distinct epitopes on the RBD: S304/site II, S309/site IV, and
S2H14/site I, the latter significantly overlapping with the RBM
(Piccoli et al., 2020). The majority of the panel were site I,
hACE2-blocking mAbs; the mAbs with sensitivity to N439K
were enriched for site I mAbs with moderate or weak/no
hACE2 blockade, consistent with the positioning of N439K at
the edge of the RBM (Figures 1A and 6F; Data S1).
To define the potential biological importance of these muta-
tions for evasion of antibody-mediated neutralization, we tested
mAbs against pseudoviruses expressing S variants N439K,
K417V, and N439K/K417V (Figures 7A–7C and S7; Data S1).
Neutralization of pseudoviruses containing these mutations
Figure 6. RBM variants exhibit escape from monoclonal antibodies and sera binding
(A and B) Binding of serum and plasma samples from 442 SARS-CoV-2 infected individuals against WT and N439K RBD plotted as (A) ELISA ED50 for each RBD
(cut-off for positive binding to WT set at 30) and (B) fold change relative to WT. Data shown are the average of two independent replicates (source data given in
Data S1). Blue dots indicate sera with at least 2-fold loss of binding to the N439KRBD variant as compared toWT in both replicates. Purple dots indicate sera from
individuals infected with SARS-CoV-2 N439K variant.
(C and D) Binding of 140 mAbs from SARS-CoV-2 infected individuals and four clinical-stage or EUA-approved mAbs against WT, N439K, K417V, and N439K/
K417V RBD, plotted as (C) ELISA AUC for each RBD and (D) fold change relative to WT. Data shown are the average of two independent replicates (source data
given in Data S1). For all, the colored dots indicate mAbs demonstrating at least 2-fold loss of binding to the variant RBD as compared to WT (counted if the
average of both replicates is at least 2-fold and each individual replicate is at least 1.7-fold).
(E) Kinetics of binding to RBD variants by Octet of six representative mAbs (representative of n = 2 independent experiments).
(F) Distribution of the 144 mAbs based on binding to RBD variants (expressed as fold-change over WT) and hACE2 competition (expressed as the mAb con-
centration blocking 80% of hACE2 binding, BC80, also indicated as a blue gradient; source data in Data S1). Higher BC80 values (lighter blue) correspond to less
hACE2 competition, with mAbs indicated at the top of the panels (white) showing no competition at all.
See also Figures S4, S5, and S6.
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that are currently in use in patients under EAU. As predicted by
its non-RBM epitope (Pinto et al., 2020), S309 was capable of
neutralizing each of these variants. We also evaluated a cross-reactive camelid nanobody, VHH-72, which has enhanced po-
tency for SARS-CoV as compared to SARS-CoV-2, predicted
to be partially due to a contact with R426 in SARS-CoV RBD,
the same position as 439 in SARS-CoV-2 RBD (Wrapp et al.,Cell 184, 1171–1187, March 4, 2021 1179
Figure 7. Neutralization of four RBM vari-
ants by a panel of antibodies and a nano-
body
(A) Neutralization of four VSV-pseudovirus variants
by six of the mAbs tested. Data shown are repre-
sentative of n = 3 biological replicates, bars = SD of
technical duplicate (Data S1).
(B) Correlation of ELISA-binding fold change and
neutralization fold change for each variant relative
to WT.
(C) Top: neutralization IC50 of the D614G virus
determined as the geometric mean of three bio-
logical replicates. Bottom: neutralization results for
all mAbs tested, expressed as a fold-change
relative to D614G (all variants are in the back-
ground of D614G) (Data S1). The individual values
of the three replicates are shown as open circles,
their geometric mean as colored bars and the
geometric SD as error bars. Each antibody is an-
notated according to its hACE2 competition (as
shown in Figure 6F) as well as its epitope (site I, II,
or IV) (Data S1). Gray boxes with a slash indicate
not tested for hACE2 competition or epitope
analysis.
See also Figure S7.
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enhanced potency against N439K SARS-CoV-2 pseudovirus
compared toWT N439 (Figures 7A and 7C), highlighting the pos-
sibility that a single mutation can impact antibody efficacy posi-
tively as well as negatively. Sensitivity of a few neutralizing mAbs
to mutations at positions 417 and 439 have also been reported in
other studies (Baum et al., 2020; Gaebler et al., 2021; Greaney et
al., 2021; Li et al., 2020a; Starr et al., 2020a; Weisblum et al.,
2020), although combinations of mutations have typically not
been evaluated. Overall, our results demonstrate that mutations
compatible with equivalent viral fitness to WT can result in im-
mune evasion from both monoclonal and polyclonal antibody
responses.
DISCUSSION
Here, we describe an example of a circulating RBM mutation,
N439K, which can evade antibody-mediated immunity without1180 Cell 184, 1171–1187, March 4, 2021losing fitness relative to WT. The success
of variants with the N439Kmutation is evi-
denced by their repeated emergence by
convergent evolution on at least nine oc-
casions, spread to 34 countries as of
January 2021, significant representation
in sampled genome sequences (indica-
tive of high infection rates), the fact that
the N439K RBD retains a high-affinity
interaction with the hACE2 receptor, and
efficient replication of N439K virus in
cultured cells. Additionally, we observed
no evidence for change in disease
severity in a large cohort of individuals in-
fected with N439K virus as compared to
WTN439 virus, althoughwe acknowledgesome limitations in the data collection, including variations in
testing guidelines and availability of testing during the course
of the study (da Silva Filipe et al., 2021).
The success of the N439Kmutation is consistent with our find-
ings that the RBM is a highly variable region of S. It demonstrates
the ability of SARS-CoV-2 to accommodate mutations at the
RBM while retaining efficient hACE2 binding. This ability could
have emerged by chance or in response to immune pressure
from neutralizing Ab responses in viral hosts. There is precedent
for the most immunogenic region of a viral surface protein to be
highly divergent despite harboring the receptor binding site; for
example, the immunogenic globular head domain of the influ-
enza virus hemagglutinin surface protein, which contains the
sialic acid receptor binding site, evolves faster than the stalk re-
gion (Doud et al., 2018; Kirkpatrick et al., 2018). The ability to
readily accommodatemutations in the RBM indicates a high like-
lihood that potentially immune-evading SARS-CoV-2 variants
will continue to emerge, with implications for reinfection,
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OPEN ACCESSArticlevaccines, and both monoclonal and polyclonal antibody
therapeutics.
A few other circulating RBM mutations have become promi-
nent since N439K first emerged. S477N appeared in the
sequence databases in March 2020 but did not become the
most prevalent RBD mutation until the summer (as of January
2021, it has >19,000 counts). Consistent with the high preva-
lence, position 477 is the RBM position where mutations are
predicted to be the most well-tolerated with respect to hACE2
binding (Figure 2). Studies across multiple mAb panels have
not found this mutation to be conferring resistance (Gaebler et
al., 2021; Greaney et al., 2021; Tortorici et al., 2020; Weisblum
et al., 2020). In contrast, mutations at position 484 in the RBM
have been reported to confer resistance to many mAbs across
multiple studies (Baum et al., 2020; Gaebler et al., 2021; Greaney
et al., 2021; Tortorici et al., 2020; Weisblum et al., 2020) and also
appeared in a persistent (>150 days) infection in an immunocom-
promised individual who did not respond to treatment with a
two-mAb cocktail (Choi et al., 2020). The variant count at posi-
tion 484 has been steadily increasing (>500 as of January
2021), and the possibility for no fitness consequences for these
variants is notable (Figures 2 and S1B) (Starr et al., 2020b), as is a
recent study identifying this position as particularly important for
escape from polyclonal serum antibodies (Greaney et al., 2021a)
and the appearance of this mutation in a new, fast-growing viral
lineage (Tegally et al., 2020). The Y453F mutation has become
noteworthy recently for its association with virus circulating in
mink farms and its transmission back to humans (Oude Munnink
et al., 2021) and the DMS measurement indicating it confers
significantly increased hACE2 binding (Starr et al., 2020b). To
date, we know of only one example of published immune escape
documented for Y453F (Baum et al., 2020), but more examples
may arise as this new mutation is investigated further. Last, the
N501Y mutation has gained notice in the final weeks of 2020
for its association with high rates of infection (Tegally et al.,
2020; Volz et al., 2021), although further research is needed to
determine the impact on immune escape.
SARS-CoV-2 appears to be evolving relatively slowly consis-
tent with its lowmutation rate, the highly susceptible human pop-
ulation, and its generalist nature (Conceicao et al., 2020) and, at
present, evidence indicates it will be controllable by vaccines
based on early SARS-CoV-2 genome sequences (Dearlove
et al., 2020). Additionally, for the majority of our tested sera
and mAbs, a single amino acid change in the RBM was not suf-
ficient to confer resistance. Nevertheless, our data indicate that
individuals with a mild antibody response to vaccination or first
infection could be at risk from a virus carrying a mutation in the
RBM. Furthermore, considering the high level of structural plas-
ticity of the RBM demonstrated in the present study, there could
be many combinations of RBM mutations, including some
requiring compensatory changes, that are compatible with
high viral fitness. Some of these combinations will contribute to
efficient immune escape. For example, our data show that
N439K can compensate for a mutation (K417V) that otherwise
decreases receptor binding affinity (Figure 4D) and that several
mAbs were more sensitive to these mutations in combination
versus individually (Figure 6D; Data S1). This particular combina-
tion of mutations is plausibly compatible with maintained viralfitness as it parallels SARS-CoV RBM:hACE2 interactions (salt
bridge at SARS-CoV RBD position R426 and no salt bridge at
V404) (Figure 4A). Current SARS-CoV-2 mutations have arisen
in the absence of pressure from significant population immunity.
However, as immunity to the WT virus becomes more wide-
spread, immune escape mutations can be expected to increas-
ingly circulate. In the final weeks of 2020, SARS-CoV-2 variants
carrying multiple mutations in the S protein, in both the RBM and
Domain A, have been observed (Volz et al., 2021) including one
variant carrying three simultaneous RBM mutations (K417N,
E484K, and N501Y) (Tegally et al., 2020). Accumulation of multi-
ple changes may increase the risk of immune escape from vac-
cines that are based on early SARS-CoV-2 sequences.
Mutations in the RBMwill also impact the prophylactic or ther-
apeutic use of mAbs. In our profile of immune escape from the
N439K variant, we observed resistance to a mAb which is part
of a two-mAb cocktail that recently received EAU. The promise
of using cocktails of mAbs is that they should significantly lower
the likelihood of drug-induced selection of resistant viruses
(Baum et al., 2020). However, if circulating viral variants already
carry resistant mutations to one antibody in the cocktail, this
could cause the cocktail to be reduced to a monotherapy. Addi-
tionally, we observed that two mutations together (N439K/
K417V) conferred resistance in vitro to the two-mAb cocktail
(Figure 7C).
Two approaches will be critical for minimizing the impact of
mAb escape mutations. One is to develop mAbs with epitopes
that are highly resistant to viral escape. This may include epi-
topes outside of the RBM and/or epitopes that are cross-reac-
tive across SARS-CoV and SARS-CoV-2, indicating conserved
epitopes with a low tolerance for mutation (Garrett Rappazzo
et al., 2021; Pinto et al., 2020; Wec et al., 2020; Wrapp et al.,
2020a). A comparison of epitopes of RBM-targeting mAbs with
themost conserved regions of the RBM (Figure 2) may also iden-
tify RBM mAbs with a higher barrier to escape. The second will
be to screen patients, likely at the population level, for the pres-
ence of potential resistance variants prior to drug administration.
The availability of multiple different mAb therapeutics in the clinic
could provide the opportunity to tailor the choice of therapeutics
to local circulating variants.
In general, given that access to therapeutic mAbs is expand-
ing, and as more people develop immune responses to the WT
virus via infection or vaccination, monitoring the evolution of
SARS-CoV-2 for escape mutants will be critical. Although we
only report on evasion of antibody-mediated immunity here, it
would be surprising if similar changes are not observed that
confer evasion of T cell immunity and innate immunity.
Limitations of study
This study presents the finding that the RBM is a highly variable
region of the SARS-CoV-2 S protein, and we provide a thorough
characterization of the N439K RBM amino acid replacement,
and the ability of this mutation to confer immune evasion without
attenuating (or enhancing) fitness or disease. When this study
was initiated in June 2020, the general consensus was that the
slow rate of evolution of SARS-CoV-2 would result in no immedi-
ate threat to vaccines or therapies. N439K was the first RBM
amino acid replacement, relative to the ancestral SARS-CoV-2Cell 184, 1171–1187, March 4, 2021 1181
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quency and so can be viewed as a sentinel mutation for SARS-
CoV-2 antigenic drift. Since initial submission to Cell in late
October 2020, the emergence of multiple highly transmissible
variants carrying other RBM mutations of significance has
brought the study of immune evasion variants to the forefront
of SARS-CoV-2 research. Future retrospective studies will
confirm whether these new RBM mutations fall into the same
category as N439K: mutations that do not attenuate viral fitness
or disease but cause immune evasion. Our results on the plas-
ticity of the RBMalso anticipated the emergence of the RBMmu-
tations present in the SARS-CoV-2 variants of concern.STAR+METHODS
Detailed methods are provided in the online version of this paper
and include the following:
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Antibodies
S304, S309 IgG and Fab fragments Pinto et al., 2020 PDB: 7JX3
S2H13, S2H14, S2A4, S2X35 IgG Piccoli et al., 2020 PDB: 7JV2, 7JXC, 7JXD, 7JXE
S2E12, S2M11 IgG Tortorici et al., 2020 PDB: 7K3Q, 7K43
LY-CoV555 IgG Eli Lilly and Company N/A
REGN10933, REGN10987 IgG Hansen et al., 2020 PDB: 6XDG
VHH-72 Wrapp et al., 2020a PDB: 6WAQ
Panel of Human IgG This study N/A
Goat Anti-Human IgG-AP Southern Biotech Cat. No. 2040-04; RRID:AB_2795643
Goat F(ab’)2 Anti-Mouse IgG(H+L), Human
ads-AP
Southern Biotech Cat. No. 1030-04; RRID:AB_2794293
Anti-Avi-tag Antibody, pAb, Rabbit GenScript Cat. No. A00674; RRID:AB_915553
Bacterial strains and pseudotype viruses





Serum and plasma of SARS-CoV-2 infected
individuals
Piccoli et al., 2020 N/A





Nasopharyngeal swabs from SARS-CoV-2
infected individuals
West of Scotland Specialist
Virology Centre
N/A
Sputum from SARS-CoV-2 infected individuals West of Scotland Specialist
Virology Centre
N/A
Chemicals and recombinant proteins
PEI MAX Polysciences Cat. No. POL24765-1
TransIT-Lenti Mirus Cat. No. 6600
4-Nitrophenyl phosphate disodium salt
hexahydrate (pNPP)
Sigma-Aldrich Cat. No. N2765-100TAB
Blocker Casein (1%) in PBS Thermo Fisher Scientific Cat. No. 37528
Tween 20 Sigma Aldrich Cat. No. 93773
Bovine Serum Albumine Sigma Cat. No. 3059
hACE2, mFc tag ATUM N/A
BioLock - Biotin Blocking Solution IBA GmbH 2-0205-050
PNGase F New England Biolabs P0704L
EndoH New England Biolabs P0702L
Thrombin Sigma-Aldrich T1063-250UN
RBD mouse Fc-tagged Sino Biological Cat. No. 40592-V05H
Streptavidin-alkaline phosphatase conjugated Jackson ImmunoResearch Cat. No. 016-050-084
Cell lines
ExpiCHO-S Thermo Fisher Scientific Cat. No. A29127
Expi293F Thermo Fisher Scientific Cat. No. A14527
Lenti-X 293T cells Takara Cat. No. 632180
Vero E6 cells ATCC Cat. No. CRL-1586
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Commercial assays, kits, and products
HiTrap Protein A columns (HiTrap Mab select PrismA) Cytiva Cat. No. 17-5498-54P
Strep-Tactin XT Superflow high capacity cartridge IBA GmbH Cat. No. 2-4026-001
HisTALON Superflow Cartridges, 5 mL Takara Bio Cat. No. 635683
HisTALON Superflow Cartridges, 1 mL Takara Bio Cat. No. 635650
Superdex 200 Increase 10/300 GL Cytiva Cat. No. 28-9909-44
Superose 6 Increase 10/300 GL Cytiva Cat. No. 29-0915-96
StrepTrap HP column, 1 mL Cytiva Cat. No. 28-9075-46
ExpiFectamine 293 Transfection Kit Thermo Fisher Scientific Cat. No. A14524
ExpiFectamine CHO Transfection Kit Thermo Fisher Scientific Cat. No. A29129
ExpiFectamine CHO Transfection Kit Thermo Fisher Scientific Cat. No. A29130
HiPrep 26/10 desalting columns Cytiva Cat. No. 17-5087-02
CaptureSelect C-tag Affinity Matrix Thermo Fisher Scientific Cat. No. 2943072010
Zeba Spin Desalting columns, 7 K MWCO, 5 ml Thermo Fisher Scientific Cat. No. 89892
Bio-Glo Promega Cat. No. G7940
Biosensor Protein A FortéBio Cat. No. 733-2137
MiSeq Reagent v2 500 cycle kit Illumina Cat. No. MS-102-2003
NextSeq 500/550 High Output Kit v2.5 (300 Cycles) Illumina Cat. No. 20024908
DMEM GlutaMAX Thermo Fisher Scientific Cat. No. 10566016
Fetal Bovine Serum (FBS) Thermo Fisher Scientific Cat. No. A4766801
DNaseI Thermo Fisher Scientific Cat. No. AM2222
Agencourt RNA Clean AMPure XP Beads Beckman Coulter Cat. No. A63987
Qubit dsDNA HS Kit Thermo Fisher Scientific Cat No. Q32854
SuperScript III Thermo Fisher Scientific Cat No. 18080044
NEBNext Ultra II Non-Directional RNA Second
Strand Synthesis Module
New England Biolabs Cat. No. E6111L
Kapa HyperPrep kit Roche Cat. No. KK8504
Kapa LTP Library Preparation Kit for Illumina Platforms Roche Cat. No. KK8232
NEBNext Multiplex Oligos for Illumina 96 Unique
Dual Index Primer Pairs
New England Biolabs Cat. No. E6442S
High Sensitivity D5000 Screentape Agilent Cat. No. 5067-5592
NEB Luna Universal Probe One-Step RT-qPCR Kit New England Biolabs Cat No. E3006E
2019-nCoV_N1 assay RT-qPCR assay Integrated DNA Technologies Cat No. 10006713
HBS-N buffer Cytiva Cat. No. BR100369
HBS-EP+ buffer Cytiva Cat. No. BR100669
Series S Sensor Chip CM5 Cytiva Cat. No. BR100530
Series S Sensor Chip C1 Cytiva Cat. No. BR100535
Mouse antibody capture kit Cytiva Cat. No. BR100838
Twin-Strep-Tag Capture Kit IBA GmbH Cat. No. 2-4370-000
EZ-Link NHS-PEG Solid-Phase Biotinylation
Kit - Mini-Spin Columns
Thermo Fisher Scientific Cat. No. 21450
Spectraplate-384 with high protein binding Perkin Elmer Cat. No. CUSG83093
Nunc-Immuno plates - 96-well plate, MaxiSorp Sigma-Aldrich Chemie GmbH Cat. No. M9410-1CS
Deposited data
SARS-CoV-2 RBD N439K/ hACE2/ S304 Fab/
S309 Fab X-ray structure
This study PDB: 7L0N
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Human antibody expression vectors (IgG1) This study N/A
Plasmids encoding SARS-CoV-2 2P S
ectodomain variants (amino acids 14-1211)
with C-terminal AviTag-8xHis-C-tag
This study (ATUM Bio) GenBank: NC_045512.2
Plasmids encoding SARS-CoV-2 RBD WT or
variants (amino acids 328-531) with C-terminal
thrombin cleavage site-TwinStrep-8xHis-tag
This study GenBank: NC_045512.2
Plasmid encoding SARS-CoV-2 RBD WT
(amino acids 328-531) with N-terminal ‘ETGT’
and C-terminal GS linker-Strep-8xHis-tag
Piccoli et al., 2020 GenBank: NC_045512.2
Plasmid encoding SARS-CoV-2 RBD N439K
(amino acids 328-531) with N-terminal ‘ETGT’
and C-terminal 8xHis-tag
This study GenBank: NC_045512.2
Plasmids encoding Sarbecovirus RBDs with
C-terminal thrombin cleavage site-TwinStrep-
8xHis-tag
This study See Data S1
Plasmid encoding human ACE2 receptor
(amino acids 19-615) plus C-terminal thrombin
cleavage site-TwinStrep-10xHis-GGG-tag
Piccoli et al., 2020 UniProt: Q9BYF1




Prism GraphPad Version 8
UNICORN Cytiva Versions 7.3 and 7.5
Biacore T200 Evaluation Software Cytiva Version 3.1
SDS software Thermo Fisher Scientific Version 2.3
Refmac5 Murshudov et al., 2011 Version 5.8.0258
Coot Emsley et al., 2010 Version 0.9
XDS Kabsch, 2010 N/A
MOE Chemical Computing Group Version 2019.0102
BioEdit Tom Hall http://bioedit.software.
informer.com/7.0
Version 7.0.5.3
R: A Language and Environment for
Statistical Computing






SPIn Liu et al., 2015 Version 1.1




ape Paradis and Schliep, 2019 Version 5.3










(Continued on next page)
ll
OPEN ACCESS
e3 Cell 184, 1171–1187.e1–e12, March 4, 2021
Article
Continued
REAGENT or RESOURCE SOURCE IDENTIFIER




Guppy basecaller Oxford Nanopore technologies Version 3.2.10





BWA Li, 2013 Version 0.7.5
iVar Grubaugh et al., 2019 Version 1.2.2
Minimap2 Li, 2018 Version 2.17
Baltic Python library https://github.com/evogytis/baltic N/A





Anaconda Version 2-2.4.0 Miniconda
Version 4.9.0
Folding@home Shirts and Pande, 2000;
Zimmerman et al., 2020
N/A
IPython Perez and Granger, 2007 Version 7.14.0
Jupyter Notebook Kluyver et al., 2016 Version 6.1.5
MDAnalysis Michaud-Agrawal et al.,
2011; Gowers et al., 2016
Version 1.0.0
NumPy https://numpy.org Version 1.19.1




PyMOL Schrödinger Version 2.3.2
ISOLDE Croll, 2018 Version 1.0.1
ChimeraX Pettersen et al., 2021 Version 1.0
AmberTools Case et al., 2017 Version 17.0
pdb-tools Rodrigues et al., 2018 Version 2.0.5









Custom code, evaluation of clinical samples This paper https://github.com/dpascall/SARS-CoV-
2-mutation-analysis
Instruments
ÄKTA Xpress FPLC Cytiva N/A
ÄKTA Pure 25 Cytiva N/A
Synergy H1 Hybrid Multi-Mode plate reader Biotek N/A
EL406 washer/dispenser BSL2 M Biotek N/A
Biacore T200 Cytiva N/A
Octet Red96 Pall FortéBio N/A
7500 Fast Real-Time PCR System Applied Biosystems N/A
Illumina MiSeq Illumina SY-410-1003
Illumina’sNextSeq550 Illumina SY-415-1002
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Flowcell R9.4.1 Oxford Nanopore
technologies
FLO-MIN106D
Envision multimode plate reader PerkinElmer 2105
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Lead contact
Further information and requests for resources and reagents should be directed to the Lead Contact, Gyorgy Snell (gsnell@vir.bio).
Materials availability
Materials generated in this study will be made available on request, but we may require a completed materials transfer agreement.
Data and code availability
Datasets generated during this study are included in the article or are available from the corresponding authors on request.
The X-ray structure data and model has been deposited with accession code PDB: 7L0N. The code used to set up, run,
and analyze the molecular dynamics simulations is available at: https://github.com/choderalab/rbd-ace2-contact-analysis.
Raw and processed molecular dynamics trajectory data are available at the MolSSI COVID-19 Molecular Structure and
Therapeutics Hub: https://covid.molssi.org//simulations/#foldinghome-simulations-of-the-sars-cov-2-spike-rbd-bound-to-human-
ace2. Code for evaluation of clinical samples is available from GitHub: https://github.com/dpascall/SARS-CoV-2-mutation-analysis.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Cell lines
Cell lines were obtained from ATCC (Vero E6) or Thermo Fisher Scientific (Expi293F, ExpiCHO-S). Expi293F and ExpiCHO-S cells
were maintained in Expi293 Expression Medium and ExpiCHO- Expression Medium (Thermo Fisher Scientific), respectively.
Sample donors
Samples from 442 SARS-CoV-2 infected individuals were obtained from the Ticino healthcare workers cohort (Switzerland),
described previously (Piccoli et al., 2020), and under study protocols approved by the local Institutional Review Board (Canton Ticino
Ethics Committee, Switzerland). All donors provided written informed consent for the use of blood and blood components (such as
PBMCs, sera or plasma). In the Ticino region of Switzerland and during the time period of collection (February-March 2020) no N439K
SARS-CoV-2 isolates were reported.
Samples from six N439K variant infected individuals were obtained from the ISARIC4C consortium (https://isaric4c.net/). Ethical
approval was given by the South Central-Oxford C Research Ethics Committee in England (reference 13/SC/0149), and by the Scot-
land A Research Ethics Committee (reference 20/SS/0028). The study was registered at https://www.isrctn.com/ISRCTN66726260.
Residual nucleic acid extracts derived from the nose-throat swabs of 1918 SARS-CoV-2 positive individuals whose diagnostic
samples were submitted to the West of Scotland specialist virology center between 3rd March and 30th June 2020 were sequenced




RBM residues were determined based on the RBD:hACE2 complex crystal structures 2AJF for SARS-CoV (Li et al., 2005) and 6M0J
for SARS-CoV-2 (Lan et al., 2020). The 2AJF structure was obtained from the PDB-REDO server (https://pdb-redo.eu) and was sub-
sequently prepared in the molecular modeling software MOE (v2019.0102, https://www.chemcomp.com) using the structure prep-
aration, protonation and energy minimization steps with default settings. RBD residues within 6.0 Å distance of any hACE2 atoms
(determined using MOE) were determined for each of the two copies of the complex in the asymmetric unit, and then were combined
to obtain the definition of the RBM used in this work (Figure 2). 6M0J was obtained from the Coronavirus Structural Task Force server
(https://github.com/thorn-lab/coronavirus_structural_task_force) and was further refined (using Refmac5 v5.8.0258), manually fitted
(using Coot v0.9) and prepared (using MOE, as described above) in multiple iterative cycles. The final structure was analyzed for
RBD-hACE2 contact residues with a 6.0 Å cutoff to obtain the RBM (usingMOE). The final list of RBM residues (Figure 1C) was arrived
at by combining the SARS-CoV and SARS-CoV-2 results.e5 Cell 184, 1171–1187.e1–e12, March 4, 2021
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SARS-CoV-2RBDand each residue in hACE2, and the total binding energy for all interactions, was determined at cutoff distances 3.0 Å,
3.5 Å, 4.0 Å, 4.5 Å, 5.0 Å, 5.5 Å, 6.0 Å, 6.5 Å and 7.0 Å. The percentage of the total binding energy for each interacting RBD residue was
calculated for each distance cutoff and was then averaged over all cutoffs. The resulting values are shown in green in Figure 1C.
RBM variability across SARS-CoV-2 sequences
Using CoV-GLUE-reported variants (http://cov-glue.cvr.gla.ac.uk/, downloaded from GISAID on November 30th 2020, n = 209,239)
the Shannon’s entropy (natural log units, as implemented in the R package entropy) was computed at each residue of the mature
(excluding signal peptide) spike protein. Then, entropy was aggregated by domain, in sliding windows (using the R package
RcppRoll), or in bins of randomly sampled residues, as detailed in figure legends. Due to the non-normal distribution of variant fre-
quencies, the median rather than the mean was used as the aggregation metric.
As an alternative to entropy, we also quantitated variability by counting the number of variants passing an increasing threshold of
supporting sequences. Unlike entropy, this metric only uses variant frequency for thresholding a digital (presence/absence) variant
call, hence it is less affected by sampling/deposition bias.
Evaluation of deep mutational scanning (DMS) data
The DMS dataset was retrieved from Starr et al. (2020b). Variant-level DMS scores were aggregated by residue by taking the min-
imum (most disruptive variant) or the average score across all variants of that residue, except for the reference amino acid and stop
codons. Alternatively, minimumand average scoreswere computed only across variants that have been observed as naturally occur-
ring. Data were represented as a heatmap annotated with: frequency of variants fromCoV-GLUE (at least 1 supporting sequence per
25,000 deposited sequences was required to call a variant); number of countries in which a variant was observed; and percentage of
total binding energy computed from an X-ray crystal structure (cf. structural analysis methods section).
Molecular dynamics simulations
Structure preparation
The RBD:hACE2 complex was constructed from individual RBD (PDB: 6m0j, Chain E) and hACE2 (PDB: 1r42, Chain A) monomers
aligned to the full RBD:hACE2 structure (PDB: 6m0j). The 1r42 structure was used for hACE2 because 1) 1r42 is higher resolution
(2.20 Å, whereas 6m0j is 2.45 Å) and 2) the electron density map of 1r42 clearly reveals N-acetylglucosamine (NAG) orientation at
each glycosylated asparagine residue, providing a reliable building block on which to construct more complex glycan structures.
These complex glycans were constructed at each NAG due to earlier work suggesting their role in mediating RBD:hACE2 binding
(Zhao et al., 2020), as it is in the spike proteins’ intrinsic RBD dynamics (Casalino et al., 2020).
In order to start from themost reliable structural models, we obtained 6m0j and 1r42 from the Coronavirus Structural Taskforce (CST)
database, which contains refined structuralmodels based on careful examination of the electron density. In the RBD of the refined 6m0j
structure, amino acid rotamers and peptide bonds were flipped to increase Ramachandran favorability, decrease rotamer
outliers, reduce clashes, and improve fit to density. A more detailed summary of the 6m0j refinement details is available at: https://
github.com/thorn-lab/coronavirus_structural_task_force/blob/master/pdb/surface_glycoprotein/SARS-CoV-2/6m0j/isolde/notes.
txt. The 1r42 refined structure differs from the PDB-deposited structure in that it includes the missing C-terminal domain of hACE2
(copied from the 6m17 PDB structure). A more detailed summary of the 1r42 refinement details is available at: https://github.com/
thorn-lab/coronavirus_structural_task_force/blob/master/pdb/human_interaction_partners/ACE2/1r42/isolde/notes.txt.
The resulting RBDand hACE2monomerswere then aligned in PyMOL2.3.2 (Schrödinger, LLC) to theCST6m0j structure to create an
initial RBD:hACE2 complex. The overall root-mean-square deviation (RMSD) was 0.426 Å and the interface RMSDwas 0.405 Å, where
RMSD was computed for all atoms and the interface residues were defined as all residues within 4 Å of the other binding partner.
Next, the full glycosylation patterns for hACE2 and RBD glycans were determined from Shajahan et al. (2020) and Watanabe et al.
(2020). For the constructed RBD:hACE2 complex, these included sites: N53, N90, N103, N322, N432, N546, and N690 on hACE2
and N343 on the RBD. The glycan structures used for each site (FA2, FA26G1, FA2, FA2, FA2G2, A2, FA2, FA2G2, respectively) corre-
spond to the most stable conformers obtained frommulti microsecond MD simulations of cumulative sampling (Harbison et al., 2019).
BaseNAG residues at the reducing end of each glycan structure were aligned to the corresponding NAG stub in the RBD:hACE2model
in PyMOL 2.3.2 (Schrödinger, LLC) and any resulting clashes were refined in ISOLDE (Croll, 2018). Full details of the glycosylation pat-
terns / structures used and full workflow are available at: https://github.com/choderalab/rbd-ace2-contact-analysis.
System solvation and parametrization
The refined glycosylated RBD:hACE2 complex was prepared for simulation using the AmberTools17 tleap suite (Case et al., 2017). All
relevant disulfide bridges were specified as well as covalent connectivity within each glycan structure. The glycosylated protein was
parameterized with the Amber ff14SB (Maier et al., 2015) and GLYCAM_06j-1 (Kirschner et al., 2008) force fields. The system was
solvated using the TIP3P rigid water model (Jorgensen et al., 1983) in a cubic box with 1.5 nm solvent padding on all sides. The sol-
vated system was then minimally neutralized with 0.15 M NaCl using the Li/Merz ion parameters of monovalent ions for the TIP3P
water model (12-6 normal usage set) (Li et al., 2015). Full details and tleap scripts can be found at: https://github.com/
choderalab/rbd-ace2-contact-analysis.Cell 184, 1171–1187.e1–e12, March 4, 2021 e6
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The system was energy-minimized with an energy tolerance of 10 kJ mol1and equilibrated using the OpenMM 7.4.2 (Eastman
et al., 2017) Langevin integrator for 300 ns in the NPT (p = 1 atm, T = 310 K) ensemble with a timestep of 4.0 femtoseconds, a
collision rate of 1.0 picoseconds -1, and a constraint tolerance of 1 3 105. Hydrogen atom masses were set to 4.0 amu by
transferring mass from connected heavy atoms, bonds to hydrogen were constrained, and center of mass motion was not
removed. Pressure was controlled by a molecular-scaling Monte Carlo barostat with an update interval of 25 steps. Non-
bonded interactions were treated with the Particle Mesh Ewald method (Darden et al., 1993) using a real-space cutoff of
1.0 nm and the OpenMM (Eastman et al., 2017) default relative error tolerance of 0.0005, with grid spacing selected automat-
ically. For improved stability, the structure was then equilibrated using the OpenMMTools 0.20.0 BAOAB Langevin integrator
(Leimkuhler and Matthews, 2013) for 10 ns using all of the same simulation parameters described above. This simulation
was subsequently packaged to seed for production simulation on Folding@home (Shirts and Pande, 2000; Zimmerman et
al., 2020). Default parameters were used unless noted otherwise. Further details of the equilibration protocol are available
at: https://github.com/choderalab/rbd-ace2-contact-analysis
Folding@home simulations
The equilibrated structure was then used to initiate parallel distributed MD simulations on Folding@home (Shirts and Pande, 2000;
Zimmerman et al., 2020). Simulations were run with OpenMM7.4.2 (Eastman et al., 2017), Folding@home core22 0.0.13). Production
simulations used the same Langevin integrator as the NPT equilibration described above. In total, 2000 independent MD simulations
were generated on Folding@home. Conformational snapshots (frames) were stored at an interval of 0.5 ns/frame for subsequent
analysis. The resulting final dataset contained 2000 trajectories, 183.8 ms of aggregate simulation time, and 367610 frames. This
amount of simulation time corresponds to approximately 13.7 GPU-years on an NVIDIA GeForce GTX 1080Ti. This trajectory dataset
with solvent is available at the MolSSI COVID-19 Molecular Structure and Therapeutics Hub: https://covid.molssi.org//simulations/
#foldinghome-simulations-of-the-sars-cov-2-spike-rbd-bound-to-human-ace2.
Simulation analysis
The longest 1000 trajectories were chosen for analysis, ranging from 90 ns to 230 ns in length, which represent an aggregate simu-
lation time of 118.7 ms. Each frame in a trajectorywas aligned usingMDAnalysis (Gowers et al., 2016;Michaud-Agrawal et al., 2011) to
the equilibrated structure. This was to ensure no crossing of periodic boundary conditions during calculation of distances between
residue pairs. The distances between residue pairs (K417-D30, E484-K31, Q493-E35, Q493-K31, G496-K353, G502-K353, Y449-
D38, Y449-Q42, K31-E35) were calculated once every 5 frames (2.5 ns) using MDAnalysis after discarding the first 100 frames
(50 ns) of each trajectory to ensure relaxation away from the initial seed conformation. Distancewas defined as theminimumdistance
between sidechain heavy atoms for a given residue pair. Further details of the analysis pipeline are available at: https://github.com/
choderalab/rbd-ace2-contact-analysis
RBM variability across Sarbecoviruses
A pairwise comparison of Sarbecovirus RBD sequences (see Table S1) to SARS-CoV-2 RBD was performed by calculating percent
identity over a window size of 30 amino acids at each RBD position. For the site-specific entropy plot across the RBD alignment of
SARS-CoV-2 and 68 related viruses, entropy for each position l (H(l)) was calculated using Shannon’s entropy formula with a natural
log as implemented in Bioedit (H(l) = -Sf(a,l)ln(f(a,l)); f(a,l) being the frequency of amino acid a at position l).
Recombinant glycoprotein production
Prefusion-stabilized SARS-CoV-2 spike protein variants (residues 14-1211), containing the 2P and Furin cleavage site mutations
(Walls et al., 2020) with a mu-phosphatase signal peptide and a C-terminal Avi-8xHis-C-tag (ATUM Bio) were expressed in Ex-
pi293F cells at 37C and 8% CO2. Transfections were performed using the ExpiFectamine 293 Transfection Kit (Thermo Fisher
Scientific). Cell culture supernatant was collected after four days and purified over a 5 mL C-tag affinity matrix (Thermo Fisher
Scientific). Elution fractions were concentrated and injected on a Superose 6 Increase 10/300 GL column (Cytiva) with 1x PBS
pH 7.4 as running buffer.
SARS-CoV-2 RBD WT (with N-terminal signal peptide and C-terminal thrombin cleavage site-TwinStrep-8xHis-tag) and variants
were expressed in Expi293F cells at 37C and 8% CO2. Transfections were performed using the ExpiFectamine 293 Transfection
Kit (Thermo Fisher Scientific). Cell culture supernatant was collected three days after transfection and supplemented with 10x
PBS to a final concentration of 2.5x PBS (342.5 mM NaCl, 6.75 mM KCl and 29.75 mM phosphates), or 3.2x for RBD N439R.
SARS-CoV-2 RBDs were purified using 1 or 5 mL HisTALON superflow cartridges (Takara Bio) and subsequently buffer exchanged
into 1x HBS-N buffer (Cytiva) or PBS using Zeba Spin Desalting or HiPrep 26/10 desalting columns.
RBDs from other sarbecoviruses and SARS-CoV-2 RBDWT (with N-terminal signal peptide and ‘ETGT’, and C-terminal GS linker-
Strep-8xHis-tag) were expressed in Expi293F cells at 37C and 8% CO2. Cells were transfected using PEI MAX (Polysciences) at a
DNA:PEI ratio of 1:3.75. Transfected cells were supplemented three days after transfection with 3 g/L glucose (Bioconcept) and 5 g/L
soy hydrolysate (Sigma-Aldrich Chemie GmbH). Cell culture supernatant (423 mL) was collected seven days after transfection and
supplemented with 47 mL 10x binding buffer (1 M Tris-HCl, 1.5 M NaCl, 20 mM EDTA, pH 8.0) and 25 mL BioLock (IBA GmbH) ande7 Cell 184, 1171–1187.e1–e12, March 4, 2021
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lowed by buffer exchange to PBS using HiPrep 26/10 desalting columns (Cytiva).
For S bindingmeasurements, recombinant ACE2 (residues 19-615 fromUniprot Q9BYF1with a C-terminal thrombin cleavage site-
TwinStrep-10xHis-GGG-tag, and N-terminal signal peptide) was expressed in Expi293F cells at 37C and 8% CO2. Transfections
were performed using the ExpiFectamine 293 Transfection Kit (Thermo Fisher Scientific). Cell culture supernatant was collected
seven or eight days after transfection and supplemented to a final concentration of 80 mM Tris-HCl pH 8.0, 100 mM NaCl, and
then incubated with BioLock (IBA GmbH) solution. After filtration through a 0.22 mm filter, ACE2 was purified using a 1 mL StrepTrap
HP column (Cytiva) followed by isolation of the monomeric ACE2 by size exclusion chromatography using a Superdex 200 Increase
10/300 GL column (Cytiva) pre-equilibrated in PBS.
For crystallography, the same hACE2 construct as above was expressed in ExpiCHO-S cells at 37C and 8% CO2 with kifunensine
added to 10 mM. Transfectionswere performed using the ExpiFectamine CHO transfection kit (Thermo Fisher Scientific). Cell culture su-
pernatant was collected six days after transfection and supplemented to a final concentration of 80mMTris-HCl pH 8.0, 100mMNaCl,
and then incubated with BioLock (IBA GmbH) solution for one hour. hACE2 was purified using a 1 mL StrepTrap HP column (Cytiva).
For SPR binding measurements with surface-captured RBD, recombinant hACE2 (residues 19-615 from Uniprot Q9BYF1 with a
C-terminal AviTag-10xHis-GGG-tag, and N-terminal signal peptide) was expressed in HEK293.sus using standard methods (ATUM
Bio). Protein was purified via Ni Sepharose resin followed by isolation of the monomeric ACE2 by size exclusion chromatography
using a Superdex 200 Increase 10/300 GL column pre-equilibrated with PBS.
For binding measurements with surface-captured hACE2, recombinant hACE2 (residues 18-615 with a C-terminal GS-IgG2a-Mm-
Fc tag, andN-terminal signal peptide) was stably transfected in CHO-K1GS knock-down cell line (ATUMBio). Proteinwas purified via
protein A and buffer exchanged into PBS.
Crystallization, data collection, structure determination, and analysis
The SARS-CoV-2 RBDN439K-hACE2 complex was formed together with two Fab fragments (S304 and S309) to aid in crystallization.
Prior to forming the SARS-CoV-2 RBD N439K-ACE2-S304-S309 complex, recombinant hACE2 protein was digested using EndoH
(New England Biolabs) and thrombin (Sigma-Aldrich). Recombinant SARS-CoV-2 RBD N439K was digested with PNGase F (New
England Biolabs) and thrombin (Sigma-Aldrich). RBD was mixed with a 1.3-fold molar excess of deglycosylated hACE2, S304
Fab, and S309 Fab. The complex was purified on a Superdex 200 10/300 GL column pre-equilibrated with 20 mM Tris-HCl pH
7.5, 150 mM NaCl. Crystals of the SARS-CoV-2 RBD N439K-hACE2-S304-S309 complex were obtained at 20C by sitting drop va-
por diffusion. A total of 200 nL of the complex at 6 mg/mLweremixed with 200 nLmother liquor solution containing 0.1M ammonium
sulfate, 20% v/v ethylene glycol, 10% w/v PEG 8000, and 0.1 M bicine/tris pH 8.5.
Data were collected at the Molecular Biology Consortium beamline 4.2.2 at the Advanced Light Source synchrotron facility in Ber-
keley, CA. Datasets from two crystals were individually processed and then merged with the XDS software package (Kabsch, 2010)
for a final dataset of 2.78 Å in space group P21. The RBD N439K-hACE2-S304-S309 complex structure was solved by molecular
replacement using phaser (McCoy et al., 2007) from starting models consisting of RBD-S304-S309 (PDB: 7JX3) and hACE2
(PDB: 6m0j). Several subsequent rounds of model building and refinement were performed using Coot (Emsley et al., 2010), ISOLDE
(Croll, 2018), Refmac5 (Murshudov et al., 2011), andMOE (https://www.chemcomp.com), to arrive at a final model for the quarternary
complex.
Binding measurements using surface plasmon resonance (SPR)
SPR binding measurements were performed using a Biacore T200 instrument. S protein was surface captured via anti-AviTag
pAb (Genscript) covalently immobilized on a CM5 chip, RBD protein was surface captured via StrepTactin XT (Twin-Strep-Tag
Capture Kit, IBA GmbH) covalently immobilized on a CM5 chip, and ACE2-mFc was surface captured via covalent immobiliza-
tion of the Cytiva Mouse antibody capture kit on a C1 chip. Running buffer was HBS-EP+ pH 7.4 (Cytiva) and all measurements
were performed at 25C. All experiments were performed as single-cycle kinetics, with a 3-fold dilution series of monomeric
hACE2 starting from 300 nM, each concentration injected for 180 s, or a 3-fold dilution series of RBD starting from 50 nM,
each concentration injected for 240 s. All data were double reference-subtracted and fit to a binding model using Biacore Eval-
uation software. For one representative replicate, capture levels were normalized to WT for visualization. Binding data with
hACE2 as analyte were fit to a 1:1 binding model. Binding data with RBD as analyte were fit to a Heterogeneous Ligand binding
model, due to an artifactual kinetic phase with very slow dissociation that arises when RBD is an analyte; the lower affinity of the
two KDs reported by the fit is reported as the KD of the RBD-ACE2 interaction (the two reported KDs are separated by at least
two orders of magnitude for all fits). The measured KD for hACE2 binding to S is likely influenced by conformational dynamics of
the RBDs in the context of the prefusion S trimer. Reported KDs are an average of 3-4 replicates measured on at least two sepa-
rate days, with error given as SEM.
Differences between the SPR assay and the published DMS binding assay (Starr et al., 2020b) include using targeted measure-
ments of purified proteins expressed in mammalian cells versus yeast surface display, as well as the use of dimeric hACE2 in the
DMS experiment, which incorporates avidity effects into the RBD-hACE2 binding measurements that can mask modest changes
in binding affinity.Cell 184, 1171–1187.e1–e12, March 4, 2021 e8
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Binding measurements of Sarbecovirus RBDs to hACE2 were performed by diluting RBDs to 8 mg/ml in kinetic buffer (PBS supple-
mented with 0.05% BSA) and immobilization on Anti-Penta-His Biosensors of an Octet RED96 system (FortéBio). RBD-coated bio-
sensors were incubated for 5 min with a solution containing 5, 1 or 0.2 mg/ml of hACE2. A dissociation step was then performed by
incubating the biosensors for 10 min in kinetic buffer. The change in material bound to the biosensors caused a shift in the interfer-
ence pattern that was recorded in real time and plotted using GraphPad Prism 8 software.
Epidemiological and genome surveillance
A national sequencing collaboration formed at the start of the epidemic in the UK, CoG-UK consortium (COVID-19 Genomics UK
(COG-UK) Consortium, 2020) has facilitated the tracking of SARS-CoV-2 sequences across Scotland since the start of the outbreak
in February 2020 and real-timemonitoring of genetic changes in the Spike gene that might be associated with changes in virulence or
transmissibility. Sequencing was carried out using an amplicon-based protocol in real-time at a rate of up to 300 genomes per week.
50% of samples were selected as surveillance samples, representing Scottish health boards proportionately based on population
size, while 50% were selected to allow intervention with local issues such as nosocomial infection in hospitals and nursing homes.
The N439Kmutation was noted to become increasingly prevalent during April 2020. This was noted to be particularly common in the
Greater Glasgow & Clyde NHS health board region but spread to adjacent Scottish health boards also.
Sequencing libraries were prepared according to the ARTIC nCoV-2019 described in detail at https://artic.network/ncov-2019.
Briefly, PCR amplicons were generated using the nCoV-2019 PrimalSeq sequencing primers using 25-35 cycles of amplification.
Generated amplicons were used to prepare either Oxford Nanopore or Illumina sequencing libraries. Oxford Nanopore libraries
were prepared as described in the link above and sequenced in a flow cell R9.4.1 (Oxford Nanopore Technologies, Part Number
FLO-MIN106D), using MinKNOW version 19.12.6. Raw FAST5 files were basecalled using Guppy version 3.2.10 in high accuracy
mode with a minimum quality score of 7. Reads were size filtered, demultiplexed and trimmed with Porechop (https://github.com/
rrwick/Porechop), and mapped against reference strain Wuhan-Hu-1 (MN908947). Variants were called using Nanopolish 0.11.3
and accepted if they had a log-likelihood score of greater than 200 and minimum read coverage of 20. For Illumina sequencing, am-
plicons were used to prepare libraries using the Kapa HyperPrep kit (Roche, Part Number KK8504) and further processed as
described in the competition assay sequencing method. Sequencing was carried out on Illumina’s MiSeq system (Illumina, Part
Number SY-410-1003) using a MiSeq Reagent v2 500 cycle kit (Illumina, Part Number MS-102-2003). Reads were trimmed with
trim_galore (http://www.bioinformatics.babraham.ac.uk/projects/trim_galore/) and mapped with BWA (Li and Durbin, 2009) to the
Wuhan-Hu-1 (MN908947) reference sequence, followed by primer trimming and consensus calling with iVar (Grubaugh et al.,
2019) and a minimum read coverage of 10.
Phylogenetic and phylodynamic analysis
UK sequences were obtained from the COG-UK consortium (https://www.cogconsortium.uk) and global sequences from the GISAID
Initiative (https://www.gisaid.org) on November 23 2020. The sequences were mapped usingminimap2 and padded against theWu-
han/WH04/2020 reference. The sequences were downsampled with weights that normalize sequence count per epiweek, maximize
the number of countries and lineages represented, and enriching for sequences with the N439K mutation. A maximum-likelihood
phylogenetic tree was constructed using IQ-TREE with the the following parameters: -czb -blmin 0.0000000001 -m HKY–runs 5
and all other parameters set to default. The tree was visualized with custom python code using the baltic library (https://github.
com/evogytis/baltic).
For the phylodynamic analysis, Scottish ‘‘introduction’’ lineages with ten or more sequences were identified (Lycett et al., 2021),
and the skygrowth package in R was used to estimate the effective population size over time (using up to ten time intervals), and the
growth rates of the lineages within Scotland (Volz and Frost, 2017). The data used for analysis were sampled between Feb 28, 2020
and Aug 18, 2020. Growth estimates were calculated for the intervals in between the time points that Ne is estimated over, from the
TMRCA onward. Lineages with less than ten sequences in total, less than 50% and/or less than five Scottish sequences were
excluded.
Evaluation of clinical samples
Clinical samples submitted to the West of Scotland Specialist Virology Centre for SARS-CoV-2 diagnostic rt-PCR testing were
selected for sequencing as part of the COVID-19 UK Genomics UK Consortium (COG-UK) project, resulting in 1918 whole genome
sequences originating from the NHS Greater Glasgow and Clyde Health Board region. Sequences were linked to electronic patient
records and basicmetadata including sample date, age, sex, admission to hospital andmortality at 28 days post diagnosis extracted.
The electronic patient records of a subset of 1591 patients underwent full case-note review and clinical severity was recorded based
on a 4-level ordinal scale: 1. no requirement for respiratory support, 2. treatment with supplemental oxygen via facemask or low-flow
nasal cannulae, 3. intubation and ventilation, non-invasive ventilation or oxygen delivery by high flow nasal cannulae devices, 4. death
within the 28 days following diagnosis.Wemodified theWHOordinal scale to these 4 points as described previously (Volz et al., 2021)
to avoid using hospitalisation as a criterion of severity because 1) many patients in nursing homes had severe infection but were not
admitted to hospital, and 2) early in the outbreak, all cases were hospitalised irrespective of the severity of their infection.e9 Cell 184, 1171–1187.e1–e12, March 4, 2021
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extend that analysis here using the same methodology to test for an effect of the N439K mutation. Additionally, we perform a new
analysis using amodel with the same structure to test for an effect of both the D614Gmutation and the D614G/N439Kmutation com-
bination on the viral load of infected patients, as measured by cycle threshold (Ct) value. Ct values were generated in different loca-
tions, on different platforms and then collected centrally.
In both cases we cannot estimate the marginal effect of the N439K mutation, as we only have the mutation on the 614G genetic
background, so the individual effect of N439K cannot be separated from any potential epistatic interactions between the mutations.
Briefly, the structure of the model used previously (Volz et al., 2021) and in the present study is a phylogenetic generalized additive
model with mutation being the primary predictor of interest. The model controls for biological sex, age and the number of days since
the first reported case in the dataset, with the latter two being included as penalised splines with amaximumof 30 knots. If the patient
was part of a cluster of cases, this was included as a random effect, with individuals not part of clusters being assigned their own
levels. Correlations driven by the rest of the genome are controlled for by a phylogenetic random effect using a correlation matrix
generated under a Brownian motion assumption from a phylogeny estimated in IQ-TREE 2 v. 2.0.6 (Minh et al., 2020) using a
HKY + G model, masking the positions recommended by (De Maio et al. 2020) as of 22/7/2020 (https://virological.org/t/
issues-with-sars-cov-2-sequencing-data/473/13), rooted on the first sequenced SARS-CoV-2 genome (Wu et al., 2020a). The priors
for the severity model were those used in the previous analysis of this data. The priors for the model of the viral load were a student-t
(mean = 20, scale = 10, degrees of freedom=3) prior on themodel intercept, a Gaussian (mean = 0, standard deviation = 10) prior over
the fixed effects, and an exponential (lambda = 0.1) prior over the random effect, penalised spline and residual standard deviations.
There are two key structural differences between the model used previously (Volz et al., 2021) and the model used here. First, mu-
tation is a three level rather than two level factor (D614/N439, D614G/N439 and D614G/N439K) with the ancestral D614/N439 being
the reference level. Second, as we are now interested in two mutations, we estimated the phylogeny used to control for the effect
of the rest of the genome excluding both the nucleotide position underlying the D614G mutation and the nucleotide position under-
lying the N439K mutation (in addition to the sites from De Maio et al. mentioned above).
The severity model used a cumulative error structure while the model on the CT values used a Gaussian error structure. In both
cases, themodels were estimated in brms v. 2.13.5 (Bürkner, 2018) . The presentedmodels had no divergent transitions, Rhat values
less than 1.01, and appropriate bulk and tail effective sample sizes for all parameters. Shortest probability intervals were calculated
using the R package SPIn v. 1.1 (Liu et al., 2015). Trees were manipulated using ape v. 5.3 (Paradis and Schliep, 2019), and dates
were manipulated using lubridate v. 1.7.4 (Grolemund and Wickham, 2011). Analysis code is available at https://github.com/
dpascall/SARS-CoV-2-mutation-analysis.
qPCR of clinical samples
All samples were tested in duplicate using the 2019-nCoV_N1 assay RT-qPCR assay (https://www.fda.gov/media/134922/download).
Ready-mixed primers and probewere obtained from IDT (Leuven, Belgium). PCRwas carried out usingNEBLunaUniversal ProbeOne-
StepRT-qPCRKit (NewEngland Biolabs, Herts, UK), primers and probe at 500 nMand 127.5 nM, respectively, and 5 mL of RNA sample
in a final volumeof 20mL. No template negative controlswere includedafter every seventh sample. Six ten-fold dilutions of SARS-CoV-2
RNA standards were tested in duplicate in each assay; standards were calibrated using a plasmid containing the N sequence that had
been quantified using droplet digital PCR. Thermal cycling was performed on anApplied Biosystems 7500 Fast PCR instrument running
SDS software v2.3 (Thermo Fisher Scientific) under the following conditions: 55C for 10 minutes and 95C for 1 minute followed by 45
cycles of 95C for 10 s and 58C for 1minute. Assayswere repeated if the reaction efficiencywas < 90%or the R2 value of the standard
curve was % 0.998. Where possible, testing of samples was repeated if the %CV of the duplicates was < 10%.
Viral growth curve
Vero E6-hACE2 cells (Vero E6 cells induced to overexpress hACE2) either with or without TMPRSS2 overexpression (S.J.R., S.B., and
A.W., unpublished data) were seeded in a 12-well plate and inoculated with an MOI of 0.01 with either the GLA1 (N439/D614G) or
GLA2 (N439K/D614G) virus isolates for 1 hr before washing the cells three times in PBS and replacing with DMEM supplemented
with 2% FBS. 100 uL of media was removed at each time point, RNA was extracted using the RNAdvance Blood kit (Beckman
Coulter), and the presence of SARS-CoV-2 determined using 2019-nCOV-N1 assays (IDT) with an NEB Luna Universal Probe
One-Step RT-qPCR Kit. A standard curve was used to determine the copy number present per mL of cell culture media. 100 uL
of the fresh media was also tested for the presence of virus, which was undetectable in all wells. Experiment was performed in trip-
licate, each with an independent preparation of virus inoculum.
Competition assay
Three T25 flasks were seeded with Vero E6-hACE2 or Vero E6-hACE2-TMPRSS2 and inoculated with either single viruses or both
GLA1 and GLA2 virus strains at an MOI of 0.01 for 1 hr. The flasks were washed three times with PBS, with 100 uL of the final
wash being retained to determine the presence of free virus, before adding 5 mL of fresh DMEM, supplemented with 2% FBS. At
24, 48, and 72 hr, 500 uL of media was removed, which was replaced with 500 uL fresh media. 300 uL was used for RNA extraction
using the RNAdvance Blood kit (Beckman Coulter) and NGS analysis of the frequencies of the specific positions within the spike pro-
tein. The single virus inoculations showed no alternations in the frequency of the amino acid positions and the final wash showing noCell 184, 1171–1187.e1–e12, March 4, 2021 e10
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genome on the Illumina NGS Next Seq platform. Briefly, extracted nucleic acid was incubated with DNaseI (Thermo Fisher Scientific,
Part Number AM2222), cleaned with RNA Ampure beads (Agencourt RNA Clean AMPure XP Beads, Beckman Coulter, Cat. No.
A63987) followed by cDNA synthesis using SuperScript III (Thermo Fisher Scientific, Part Number 18080044) and NEBNext Ultra
II Non-Directional RNA Second Strand Synthesis Module (New England Biolabs, Part Number E6111L). Samples were further pro-
cessed using the Kapa LTP Library Preparation Kit for Illumina Platforms (Roche, Part Number KK8232) and indexed with the NEB-
Next Multiplex Oligos for Illumina 96 Unique Dual Index Primer Pairs (New England Biolabs, Part Number E6442S). Libraries were
characterized utilizing using the Qubit dsDNA HS Kit (Thermo Fisher Scientific, Cat No. Q32854) and the sequenced on Illumina’s
NextSeq 550 System (Illumina, Part Number SY-415-1002), using a NextSeq 500/550 High Output Kit v2.5 (300 Cycles) (Illumina,
Cat. No. 20024908) generating aproximately 10 million pairs of reads per sample. Experiment was performed in triplicate, each
with an independent preparation of virus inoculum.
Ab discovery and recombinant expression
Human mAbs were isolated from plasma cells or memory B cells of SARS-CoV or SARS-CoV-2 immune donors, as previously
described (Corti et al., 2011; Pinto et al., 2020; Tortorici et al., 2020). Recombinant antibodies were expressed in ExpiCHO cells
at 37C and 8% CO2. Cells were transfected using ExpiFectamine. Transfected cells were supplemented 1 day after transfection
with ExpiCHO Feed and ExpiFectamine CHO Enhancer. Cell culture supernatant was collected eight days after transfection and
filtered through a 0.2 mm filter. Recombinant antibodies were affinity purified on an ÄKTA xpress FPLC device using 5 mL HiTrap
MabSelect PrismA columns followed by buffer exchange to Histidine buffer (20 mM Histidine, 8% sucrose, pH 6) using HiPrep
26/10 desalting columns.
Enzyme-linked immunosorbent assay (ELISA)
A total of 144 human monoclonal antibodies or 442 human sera were tested for binding to RBD WT and mutants, as previously
described (Piccoli et al., 2020). Spectraplate-384 plates with high protein binding treatment (custom made from Perkin Elmer)
were coated overnight at 4 C with 0.1 mg/mL (for mAbs) or 5 ug/mL (for sera) SARS-CoV-2 RBD WT, N439K, K417V or N439K/
K417V in phosphate-buffered saline (PBS), pH 7.2. Plates were subsequently blocked with Blocker Casein 1% supplemented
with 0.05% Tween 20 (Sigma-Aldrich) for 1 h at room temperature. The coated plates were incubated with serial dilutions of the
monoclonal antibodies or of the sera for 1 h at room temperature. The plates were then washed with PBS containing 0.05%
Tween-20 (PBS-T), and alkaline phosphatase-goat anti-human IgG (Southern Biotech) was added and incubated for 1 h at room tem-
perature. After 3 washing steps with PBS-T, p-NitroPhenyl Phosphate (pNPP, Sigma-Aldrich) substrate was added and incubated for
30 min at room temperature. The absorbance of 405 nmwas measured by a microplate reader (Synergy H1 Hybrid Multi-Mode plate
reader, Biotek). For mAbs, fitting was performed using the drc R package with a 4-parameter logistic (4PL) model, yielding dose-
response curves from which the area under the curve (AUC) between 5 and 500 ng/mL was computed. The AUC allows to capture,
in a single metric, shifts in two parameters of the 4PLmodel: EC50 and upper asymptote. For sera, fitting was performed using Graph-
Prism 8 with a 4PLmodel from which ED50 was calculated. A cutoff of 30 for serum ED50 was set based on previously published data
(Piccoli et al., 2020). A difference in reactivity to RBD mutants compared to WT was considered when a minimum 2-fold-variation in
the AUC or ED50 WT/mutant ratios was observed in two independent experiments (for mAbs, fold variation as low as 1.7 was
accepted provided that the average of two experiments was greater or equal to 2-fold).
Antibody binding measurements using bio-layer interferometry (BLI)
BLI binding measurement was performed on a selection of human monoclonal antibodies tested by ELISA (16/144). Antibodies were
diluted to 2.7 mg/mL in kinetic buffer (PBS supplemented with 0.05% BSA) and immobilized on Protein A Biosensors of an Octet
RED96 system (FortéBio). Antibody-coated biosensors were incubated for 5 min with a solution containing 5 mg /mL of SARS-
CoV2 RBDWT, N439K, K417V or N439/K417V in kinetic buffer. A dissociation step was then performed by incubating the biosensors
for 5 min in kinetic buffer. Change inmolecules bound to the biosensors caused a shift in the interference pattern that was recorded in
real time and plotted using GraphPad Prism 8 software.
Blockade of RBD binding to ACE2
Blockade of WT RBD binding to hACE2 was performed, as previously described (Piccoli et al., 2020). Unlabeled mAbs were serially
diluted, mixed with RBD mouse Fc-tagged antigen (Sino Biological, final concentration 20 ng/mL) and incubated for 30 min at 37C.
Themix was added for 30min to ELISA 96-well plates (Corning) pre-coated overnight at 4Cwith 2 mg/mL hACE2 in PBS. Plates were
washed (EL406 washer/dispenser BSL2M, Biotek) and RBD binding was revealed using a secondary goat anti-mouse IgG (Southern
Biotech). After washing, pNPP substrate was added and plates were read at 405 nm (Synergy H1 Hybrid Multi-Mode plate reader,
Biotek). The percentage of inhibition was calculated as follow: (1(OD sampleOD neg ctr)/(OD pos ctrOD neg ctr)) 3 100.
RBD epitope mapping (blockade of binding assay)
RBD epitope mapping of the 144 mAbs was performed through blockade of binding (BOB) assay as previously described (Piccoli
et al., 2020). Human mAbs binding to RBD site I (S2H14), site II (S304) and site IV (S309) were biotinylated using the EZ-Linke11 Cell 184, 1171–1187.e1–e12, March 4, 2021
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of each mAb to achieve 80% maximal binding was determined. Unlabeled mAbs were serially diluted and added to ELISA 96-well
plates (Corning) pre-coated overnight at 4C with 1 mg/mL of RBD mouse Fc-tagged antigen (Sino Biological) in PBS. After 30 min,
biotinylated anti-RBDmAbswere added at the concentration achieving 80%maximal binding and themixturewas incubated at room
temperature for 20 min. Plates were washed (EL406 washer/dispenser BSL2 M, Biotek) and antibody binding was revealed using
alkaline phosphatase-conjugated streptavidin (Jackson ImmunoResearch). After washing, pNPP substrate (Sigma-Aldrich) was
added and plates were read at 405 nm (Synergy H1 Hybrid Multi-Mode plate reader, Biotek). The percentage of inhibition was calcu-
lated as follow: (1(OD sampleOD neg ctr)/ (OD pos ctrOD neg ctr)) 3 100.
VSV pseudovirus generation
Replication defective VSV pseudovirus (Takada et al., 1997) expressing SARS-CoV-2 spike protein were generated as previously
described (Riblett et al., 2015) with some modifications. Plasmids encoding SARS-CoV-2 spike variants were generated by site-
directed mutagenesis of the wild-type plasmid, pcDNA3.1(+)-spike-D19 (Giroglou et al., 2004). Lenti-X 293T cells (Takara,
632180) were seeded in 10-cm dishes at a density of 1e5 cells/cm2 and the following day transfected with 5 mg of spike expression
plasmid with TransIT-Lenti (Mirus, 6600) according to themanufacturer’s instructions. One day post-transfection, cells were infected
with VSV-luc (VSV-G) (Kerafast, EH1020-PM) for 1 h, rinsed three times with PBS, then incubated for an additional 24 h in complete
media at 37C. The cell supernatant was clarified by centrifugation, filtered (0.45 mm), aliquoted, and frozen at 80C.
Pseudovirus neutralization
Vero E6 cells (ATCCCRL-1586) were grown in DMEMsupplementedwith 10%FBS and seeded into clear bottomwhite 96well plates
(Costar, 3903) at a density of 2e4 cells per well. The next day, mAbs were serially diluted in pre-warmed complete media, mixed at a
1:1 ratio with pseudovirus and incubated for 1 h at 37C in round bottom polypropylene plates. Media from cells was aspirated and
50 mL of virus-mAb complexes were added to cells and then incubated for 1 h at 37C. An additional 100 mL of prewarmed complete
media was then added on top of complexes and cells incubated for an additional 16-24 h. Conditions were tested in duplicate wells
on each plate and at least six wells per plate contained uninfected, untreated cells (mock) and infected, untreated cells (‘nomAb con-
trol’). Virus-mAb-containing media was then aspirated from cells and 100 uL of a 1:4 dilution of Bio-glo (Promega, G7940) in PBSwas
added to cells. Plates were incubated for 10 min at room temperature and then were analyzed on the Envision plate reader
(PerkinElmer). Relative light units (RLUs) for infected wells were subtracted by the average of RLU values for the mock wells (back-
ground subtraction) and then normalized to the average of background subtracted ‘‘no mAb control’’ RLU values within each plate.
Percent neutralization was calculated by subtracting from 1 the normalized mAb infection condition. Data were analyzed and visu-
alized with Prism (Version 8.4.3). IC50 and IC80 values were calculated from the interpolated value from the log(inhibitor) versus
response – variable slope (four parameters) nonlinear regression with an upper constraint of < 100. Each neutralization experiment
was conducted on three independent days, i.e., biological replicates, where each biological replicate contains a technical duplicate.
IC50 values across biological replicates are presented as geometric mean ± geometric standard deviation. The loss or gain of neutral-
ization potency across spike variants was calculated by dividing the variant IC50 by the parental (D614G) IC50 within each biological
replicate, and then visualized as geometric mean ± geometric standard deviation.
QUANTIFICATION AND STATISTICAL ANALYSIS
Quantification and statistical analyses were performed using GraphPad Prism (v8), R, and Biacore T200 Evaluation software, as
described in the Method details.Cell 184, 1171–1187.e1–e12, March 4, 2021 e12
Supplemental Figures
Figure S1. High RBM variability in deposited SARS-CoV-2 sequences is consistent with a dynamic RBD:hACE2 binding interface, related to
Figures 1 and 2
(A) Number of observed variants in four S domains (or full mature S protein) normalized by the total number of residues in each domain, where the number of
observed isolates required to call a variant is varied along the x axis.
(B) Distributions of distances observed for RBD (gray):hACE2 (gold) residue pairs: K417-D30, E484-K31, Q493-K31, Q493-E35, G496bb-K353, G502bb-K353bb,
Y449-Q42, Y449-D38, K31-E35 (bb = backbone interaction). RBD:ACE2 residue pairs were chosen based on RBM residues with high binding energies as
determined by the binding energy % column (green) in Figure 2. Distances were computed every 2.5 ns from 118.7 ms of molecular dynamics simulation data.
Dashed lines indicate a distance of 3.5 Å and the percentage of distances below and above 3.5 Å are annotated to the left and right of the lines, respectively.
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Figure S2. RBDs from bat and pangolin Sarbecovirus isolates bind to hACE2 despite RBM divergence, related to Figures 1 and 2
(A) Top – Percent identity to SARS-CoV-2 using a sliding window size of 30 amino acids for seven related Sarbecoviruses (see figure key, *: viruses which bind to
hACE2) across the RBD region of the Spike protein. Bottom – Site-specific entropy plot across the RBD protein alignment of SARS-CoV-2 and 68 related viruses
(Table S1). Sites constituting the RBM are annotated in blue; the x axis refers to absolute positions in the SARS-CoV-2 Spike protein sequence. Right – boxplot of
site-specific entropy values for the RBM sites (blue) and the full RBD (gray).
(B) Sequence alignment (left) and identity for RBM and RBD (right) to SARS-CoV-2 of the RBD sequences showing binding to hACE2. RBM residues indicated by
blue boxes.
(C) Binding of hACE2 to human, pangolin, and bat Sarbecovirus RBDs by BLI. Bat CoV RaTG13, Bat CoVs ZC45, BtKY72 and BGR2008 have also been tested
and did not bind hACE2.
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Figure S3. Virological and clinical results stratified by positions 439 and 614, related to Figures 3 and 5
(A) Phylodynamic analysis showing lineage growth rates relative to sampling times for UK lineages in Scotland. Data used for analysis were sampled between Feb
28, 2020 and Aug 18, 2020 (see STARmethods and http://sars2.cvr.gla.ac.uk/RiseFallScotCOVID/). The Scottish N439K lineage i (which co-occurs with D614G)
is indicated in black along with whether wild-type N439 lineages are D614 (red) or D614G (blue). The inset shows a boxplot for the distributions of these
genotypes. Note, only the growth rates between 50 and 50 are plotted.
(B) Comparison of clinical severity between D614/N439, D614G/N439 and D614G/N439K genotypes by patient age group for 1591 patients whose diagnostic
sampleswere sequenced. Ordinal scale scored by oxygen requirement: 1. No respiratory support, 2: Supplemental oxygen, 3: Invasive or non-invasive ventilation
or oxygen delivery by high flow nasal cannulae, 4: Death.
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Figure S4. Sera ELISA results, related to Figure 6
ELISA binding of the 33 human sera with a > 2-fold reduction of binding to RBD N439K (A) and of the 6 sera of individuals infected with SARS-CoV-2 N439K
viruses (B) to RBD WT (gray), N439K (blue), K417V (yellow) and N439K/K417V (red). Representative of n = 2 independent experiments.
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Figure S5. mAb ELISA results, related to Figure 6
ELISA binding of 80 out of the 144 mAbs to RBD WT (gray), N439K (blue), K417V (yellow) and N439K/K417V (red). AUC used for quantification is highlighted
between dotted lines. Representative of n = 2 independent experiments. See Data S1 for results of all 144 mAbs.
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Figure S6. mAb BLI results, related to Figure 6




Figure S7. VSV pseudovirus neutralization curves of all mAbs tested, related to Figure 7
Representative of n = 3 biological replicates, bars = SD of technical duplicate.
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